During the years I owned Dansco, one of our more curious and persistent product lines revolved around dimethyl sulfoxide, or DMSO. Back then, we bought it in industrial barrels, a translucent solvent with a distinctive garlic-like odor, and repackaged it into bottles for athletes, physical therapists, and people seeking relief from chronic muscle and joint pain. DMSO occupied an odd place between folk remedy and emerging clinical interest; to customers, it often represented hope more than hard science.
Our customers were a cross-section of the athletic and therapeutic communities. Semi-professional cyclists and runners came in with recurring strains; rodeo competitors and weekend weightlifters sought faster recovery after heavy sessions. Physical therapists occasionally ordered larger quantities for clinic use. We also supplied hobbyists who used DMSO as a carrier to deliver other compounds topically. Labels and conversations emphasized topical application and anecdotal reports—reduced inflammation, quieter joint pain, and accelerated soft-tissue healing were commonly cited. Word-of-mouth drove most sales; a single convincing testimonial could send a dozen people through our doors.
Operationally, Dansco HiLight handled the product carefully. We sourced pharmaceutical-grade DMSO where possible, filtered and decanted it, and provided clear instructions: use gloves, test a patch of skin first, avoid open wounds, and expect a transient odor as it metabolized through the skin. We sold it in a range of concentrations and bottle sizes to accommodate different users. For some customers, the solvent’s ability to penetrate skin and carry small molecules fascinated them; for others, it was a straightforward topical analgesic.
Years ago, DMSO’s reputation was shaped by a mixture of legitimate research, experimental clinical trials, and a vast body of anecdote. In veterinary medicine, it gained faster acceptance—particularly in equine care for reducing inflammation—than in human medicine due to differing regulatory pathways. Media stories sometimes amplified miraculous cures, while regulatory agencies cautioned that evidence for systemic benefits remained limited and that there were potential side effects, including skin irritation and changes in taste or smell.
Those regulatory tensions influenced how we marketed and supported the product. We avoided making medical claims, focused on user education, and maintained open dialogue with customers about both benefits and risks. Occasionally, a customer reported dramatic short-term relief; just as often, someone saw little change. The variability underscored how personal and situational topical therapies can be.
Reflecting now, decades later, it’s striking how cycles of acceptance and skepticism recur. DMSO never disappeared—its niche persisted in sports, veterinary care, and among people drawn to alternative therapies. Dansco’s experience felt emblematic of that cycle: a small business acting as a bridge between raw chemical suppliers and end users, supplying a controversial but enduring compound with cautious stewardship. Those dusty barrels and the conversations around them are part of a larger story about how communities experiment with remedies outside mainstream medicine, how anecdote and evidence interact, and how small entrepreneurs navigate the margins of changing scientific and regulatory landscapes.
Many of those memories live in boxes and ledgers now, but they shaped our approach to customer service, safety, and skepticism. We trained staff to listen, document experiences, and encourage consultation with healthcare professionals. Although the science around DMSO has evolved, Dansco’s legacy remains: a practical, cautious engagement with a compound that sits at the intersection of chemistry, care, and current small-business stewardship and history.
Leave a Reply